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Asthma in children 
 
Asthma affects 1.1 million children in the UK and is the most common long-term condition 
of childhood. The prevalence of childhood asthma symptoms in the UK is amongst the 
highest worldwide and this contributes to the estimated £1 billion annual cost of asthma care 
to the NHS. Children still die from asthma despite advances in management and mortality 
rates have changed very little over the past 20 years. The recent national review of asthma 
deaths provided a stark reminder of “why asthma still kills” and made key recommendations 
for children with asthma. However, evidence-based recommendations are still poorly 
implemented. This article seeks to enthuse the next generation of GPs to prioritise the 
improvement of asthma care in children.  
 
Asthma is characterised by bronchial hyper-reactivity, chronic inflammation and obstructive 
airways disease that varies over time. The associated respiratory symptoms of wheeze, 
breathlessness, cough and chest tightness can also vary over time and in severity.  
An estimated 1 in 11 children in the UK has asthma and the prevalence of asthma is one of 
the highest in the world (Asthma UK, 2014). Boys aged 5-14 years present most frequently to 
primary care with 95 consultations for every 1000 registered patients (Information Services 
Division (ISD) Scotland, 2013). However, from age 15 years onwards female patients consult 
more frequently than male patients (ISD Scotland, 2013).  
In the UK, over a third of all asthma attacks requiring hospital admission in 2011/12 were for 
children. Moreover, in 2012/13, 28 children and young people (including 10 under 10 year 
The GP curriculum and asthma in children 
Clinical module 3.19: Respiratory health requires GPs to: 
• Know the diagnostic and treatment guidelines for common respiratory diseases 
(asthma, COPD, lung cancer) in primary care  
• Know the boundaries of primary care management and the role of specialist services in 
supporting the patient 
• Explain, encourage and support self-management strategies for different respiratory 
diseases, according to the differing wishes and expectations of patients 
Clinical module 3.04 :Care of children and young people requires GPs to: 
• Provide information on medicines to patients in a clear way that is appropriate to their 
understanding as children, young people and parents 
olds) died from asthma in the UK (Levy et al., 2014). Asthma remains a ‘killer disease’, with 
deaths occurring even in children with mild disease. In primary care there is a clear duty to 
attend promptly to acute asthma attacks but the prevention of asthma attacks also deserves 
attention and determined effort if mortality and morbidity are to be improved. Now that 
practice nurses complete more consultations for asthma than GPs (ISD Scotland, 2013), 
doctors may have become less confident, or even complacent, in the routine management of 
asthma. 
Perhaps a change of mindset is needed in general practice. An exacerbation of asthma should 
be viewed as a treatment failure. Failure can occur for different reasons including: 
deficiencies in treatment, patient education or understanding; a lack of supported self-
management or regular review; poor adherence and poor inhaler technique. Every effort 
should be made to prevent treatment failure but in addressing such failures of treatment it is 
appropriate to consider first how to make the diagnosis of asthma as this precedes treatment 
for asthma. 
Diagnosis  
There is no definitive gold standard test which can categorically confirm the diagnosis of 
asthma. Instead, asthma is diagnosed according to evidence collected from a structured 
clinical assessment, together with (ideally) confirmation of variable airflow obstruction e.g. 
by spirometry or serial peak expiratory flow readings (British Thoracic Society / Scottish 
Intercollegiate Guideline Network (BTS/SIGN), 2016).   
Insert figure 1 
History 
Suspect asthma in any child experiencing more than one of the following symptoms:  
• Wheeze 
• Breathlessness 
• Cough or  
• Episodic chest tightness.  
Recurrent episodes may be triggered by exposure to allergens, viral infection, or exacerbated 
by exercise, cold air, emotion or laughter. Diurnal variation of symptoms is common, with 
symptoms being worse at night or in the early morning. Remember to ask about existing 
atopic conditions, such as eczema or allergic rhinitis and a family history of atopy or asthma: 
if present, the likelihood of asthma is higher.  
Examination 
Respiratory examination may well be normal if the child is asymptomatic, so it is important 
not to exclude asthma solely on examination findings. Examination should not just include 
the respiratory system.  Examine the throat for enlarged tonsils as these may be associated 
with obstructive sleep apnoea (snoring and noisy breathing at night), or co-exist with 
adenoidal enlargement (promote mouth-breathing and contribute to a dry, irritant cough 
during sleep). Examine the skin and nose for signs of atopy. Wheeze in asthma tends to be 
scattered, polyphonic and end-inspiratory. If wheeze is never heard during symptomatic 
episodes, alternative diagnoses should be considered. Consider the symptoms and signs 
which suggest diagnoses other than asthma (Table 1). 
Insert Table 1 
Further investigation 
It is important to recognise that a structured clinical assessment should incorporate all 
available evidence. The history and examination are key components, but information from 
the child’s record could help in the diagnosis of asthma. For example a past entry of wheeze 
heard on chest auscultation recorded by a doctor or nurse; a previous blood test showing 
eosinophilia; past skin prick test results showing positivity for aeroallergens (BTS/SIGN 
2016).  
Currently not widely available in UK general practice, fractional exhaled nitric oxide 
(FeNO), is quick and can be performed by children aged 5 or older. A positive FeNO test can 
demonstrate airways inflammation and increases the probability of asthma, however, a 
negative test does not exclude asthma (BTS/SIGN, 2016). 
With the initial assessment complete, decide how to proceed based on the probability that the 
child has asthma. The pathways are outlined in table 2.  
Insert table 2 
Chest X-ray 
A chest X-ray is not necessary in the diagnostic work up of a child with suspected asthma. 
However, it may be considered for cases where an alternative condition is suspected or in 
severe disease (BTS/SIGN, 2016).   
Avoiding over-diagnosis 
Wrongly labelling children with a diagnosis of asthma can lead to unnecessary treatment and 
anxiety (Looijmans-van den Akker, van Luijn & Verheij, 2016). The variable nature of 
asthma can mean that individuals may experience long periods without symptoms and it is 
not infrequent that asthma in children remits (Strachan, Butland, & Anderson, 1996). To 
discern between over-diagnosis and ‘inactive’ asthma, it is essential to record the basis on 
which a diagnosis was made so that, if questioned later, it can be reviewed (BTS/SIGN, 
2016). Secondly, prescription of asthma treatment should always be accompanied by on-
going review and reassessment, with a view to reducing or ultimately stopping medication if 
a child remains symptom-free. 
If a child is commenced on a trial of treatment (usually inhaled corticosteroids), it should be 
for a maximum of 6 weeks, and stopped at the end of the trial, regardless of the clinical 
picture (Bush & Fleming, 2016). If the child has had no response to treatment (ideally based 
on objective results), the diagnosis of asthma is unlikely. If, however, symptoms improve 
with inhaled corticosteroids but recur when stopped and then settle again with reintroduction 
of treatment, a diagnosis of asthma can be made. If a trial of treatment is started it is 
important to ensure that the dosage is correct and that the treatment is given correctly. This 
can be achieved by early referral to the practice or respiratory nurse for education on inhaler 
technique and other aspects of self-management. 
Management 
The goal of asthma management is disease control. This is defined as no day or night 
symptoms, leading an unrestricted lifestyle (including being able to exercise freely), having 
no need for rescue medication, experiencing no asthma attacks and achieving the best 
possible lung function, with the fewest medication side-effects possible (BTS/SIGN, 2016).  
Intermittent reliever therapy 
Short acting β2 agonists (salbutamol) should be prescribed as a short-term reliever of 
symptoms. In a minority of children with mild intermittent asthma or mild exercise-induced 
asthma, it may be possible to treat with occasional reliever therapy only (BTS/SIGN, 2016).  
Children with good asthma control should need little or no short acting β2 agonists. If children 
are being issued with regular repeat prescriptions for salbutamol inhalers then this raises 
questions about their asthma management. Is their asthma poorly controlled? Are they using 
their inhaler(s) correctly? Overuse of short acting β2 agonists and underuse of inhaled 
corticosteroids is common, and was highlighted as a key action point by the national review 
of asthma deaths (Levy et al., 2014).  Children requesting more than one short acting β2 
agonists a month should be contacted to clarify their usage and have their asthma assessed 
(BTS/SIGN, 2016).  
Suspected asthma: monitored initiation of treatment 
Following diagnosis of asthma or as a trial of treatment with a suspicion of asthma, a very-
low-to-low dose inhaled steroid should be commenced (Figure 2). To bring clarity to the 
comparative strengths of different inhalers, the BTS/SIGN (2016) update has listed doses of 
inhaled corticosteroids as very low (usually paediatric doses), low, medium and high. Clenil 
Modulite can be prescribed by trade name as it is currently the only pressurised metered dose 
inhaler (pMDI) CFC-free product with a paediatric licence.  A dose of 100 microgram twice 
daily would be a recommended starting point, with follow up arranged at 6 weeks.  
Insert figure 2 here 
Regular preventer 
If the initiation period is successful, treatment should be continued as regular preventer 
therapy. The dose of inhaled corticosteroids can be optimised over time up to a maximum of 
200 microgram twice daily. Remember that long-term inhaled corticosteroid of 
400microgram (budesonide diproprionate and equivalent) or more a day may lead to systemic 
side-effects such as growth failure and adrenal suppression (BTS/SIGN, 2016); children on 
these doses long term should be reviewed by a hospital specialist. At each increase of dose, 
children should be reviewed and the response to treatment assessed, with height and weight 
monitored annually.  Ultimately, the aim is to achieve disease control at the lowest possible 
dose of inhaled corticosteroid. 
Initial add-on preventer  
Long acting bronchodilators are licensed for use in children aged 5 years and above, as add-
on therapy.  Evidence from Weatherall et al. (2010) cautions against the use of long-acting 
beta agonist (i.e. salmeterol) as a monotherapy due to the increased risk of asthma mortality.  
Accordingly, and particularly as adherence with any long-term condition is a challenge, all 
long-acting bronchodilators should be prescribed as a combination therapy. 
Montelukast is an alternative add on therapy for the over 5s or can be considered for use as a 
monotherapy in the under 5s (BTS/SIGN, 2016).  As an oral preparation, it is generally well 
tolerated with relatively few side-effects and is given at bedtime. Montelukast should be 
discontinued if there is no perceived clinical benefit after a trial period of 3 months. 
Children can often have seasonal asthma dependant on trigger factors, so it may be feasible to 
reduce and even discontinue therapies out of season.  With any step down in therapy, parents 
should be given clear self-management advice on home asthma monitoring and when to 
increase treatment and seek medical review.   
High-dose therapies 
A proportion of children will continue to experience symptoms despite add on therapies.  
Prior to referral to secondary care (Box 1), assess adherence to treatment by reviewing repeat 
prescriptions, inhaler technique and the child’s asthma action plan to ensure the family fully 
understands the plan and when to take the medication. Ensure that any under-treated rhinitis 
is managed with nasal steroids and antihistamines (Scadding et al., 2007). Other existing co-
morbidities and tobacco smoke in the household may also limit response to treatment. Finally 
remain open-minded – could ongoing symptoms and failure of treatment be the result of an 
incorrect diagnosis of asthma? 
Insert Box 1 
Supported self-management 
Supported self-management is a key component of asthma care, that should be provided 
routinely for every child with asthma. Asthma self-management should include education 
about self-monitoring of symptoms (or peak expiratory flow), regular medical review and a 
personal asthma action plan (Gibson et al., 2002). Education should be patient-centred and 
tailored to the child and parent’s understanding, encompassing topics such as: recognising 
and responding to worsening asthma control, identifying and avoiding individual triggers, 
peak expiratory flow monitoring (if preferred) and inhaler use. Keep in mind the dangers of 
smoking for a child with asthma and, if appropriate, offer smoking cessation support to 
parents. 
Annual review by a doctor or nurse will provide an opportunity to confirm the diagnosis, the 
treatment and self-management plan. Reviews  may be more frequent according to individual 
patient needs. Any asthma attack that leads to an emergency visit to hospital is an indicator of 
risk in the future: the child should be reviewed in primary care within 2 days (Bush and 
Fleming, 2015). 
Supported self-management is effective. There are benefits for the child, including  better 
asthma control, reduced absence at school, reduced emergency department visits, hospital 
admissions and unscheduled appointments (Boyd et al., 2009; Gibson et al., 2002).  
Completing a personal asthma action plan 
Personal asthma action plans (Figure 3) are an important aspect of self-management and have 
been validated for children 5 years or older (Boyd et al., 2009). Despite the known benefits, 
less than a third of asthma patients have one (Asthma UK, 2014). An asthma action plan 
provides written guidance of current treatment, triggers to avoid and steps to take if asthma 
control deteriorates. Completing an action plan together with a parent and child provides a 
good structure for discussing management, so it is important to be familiar with the content, 
and know how to access one easily either through an asthma template on general practice 
software or directly from a website such as Asthma UK   (asthma.org.uk).  
Insert figure 3 here 
Monitoring asthma control can be based on parent and child recognising worsening 
symptoms, or in older children, a drop in peak expiratory flow. If peak expiratory flow is 
used, the percentage of personal best (not predicted) is best (Gibson & Powell, 2004). Widely 
accepted thresholds for treatment are a fall in peak flow to 80% of personal best for starting 
regular reliever medication for a defined period (BTS/SIGN, 2016): 4 puffs 4 times a day for 
4 days is a useful guide. The recommendation to seek urgent clinical advice is based on the 
severity of symptoms and a fall in peak expiratory flow below 50% of personal best. 
Acute management 
BTS/SIGN (2016) provide clear age-appropriate guidance for the assessment and 
management of children presenting with an asthma attack (Figure 4). To build on the 
guideline, the following section considers practical points and common pitfalls. 
Insert figure 4 here 
Oxygen saturation monitoring - professionals and parents 
Having access to a pulse oximeter is essential in the assessment of children with acute 
wheeze. However, care should be taken when using equipment not intended for paediatric use 
as it can produce incorrect readings.  
Pulse oximeters are readily available for parents to purchase and may be used at home to 
make assessments regarding their own child. Whilst there is no evidence to support or refute 
the use of saturation monitors as part of a personalised asthma action plan, using a monitor 
without the knowledge and skills to interpret and act upon results leads to risks. In particular, 
the importance of interpreting results in the context of the whole clinical picture and not in 
isolation should be stressed (Welsh and Carr, 2013). 
Children under 2 years 
Children under the age of 2 who present acutely wheezy are most likely to have bronchiolitis, 
in which case, prednisolone is unlikely to provide any clinical benefit (Fernandes et al., 
2013).  Each child, however, should be assessed individually as the child may have multi-
trigger wheeze or a personal or family history of atopy that may increase the probability of an 
asthma diagnosis.  If steroids are prescribed, it is important to document clinical response and 
time to resolution of symptoms.  
Children over 2 years 
Acute wheeze has been treated with ‘multi-dose’ salbutamol in the majority of secondary 
care settings since the early 2000s and this has increasingly become the norm in primary care.  
The benefits when compared to nebulised beta-agonist include a reduced length of stay in the 
emergency department, a lower heart rate and fewer systemic side-effects (Cates et al., 2013).  
Additionally, parents are able to instigate emergency treatment at home as part of their 
asthma action plan and reinforces to them the need to seek urgent medical review if this is 
ineffective.  BTS/SIGN (2016) advises a dose of 200 microgram (2 puffs) to 1000 microgram 
(10 puffs), depending on the severity of symptoms. However, the majority of hospitals in the 
UK consider 10 puffs as the ‘multi-dose’. 
Nebuliser – when and how? 
The use of air driven nebulisers for the treatment of acute severe wheeze should be 
discouraged.  Salbutamol given via an air driven nebuliser results in pulmonary vasodilation, 
increasing perfusion to poorly ventilated lung units and ventilation-perfusion mismatch. 
Worsening hypoxaemia results and has led to the death of a child in a primary care setting 
(Inwald et al., 2001). Therefore, in the event of being faced with a child presenting with 
severe wheeze, a nebuliser should be administered via oxygen at a flow rate of 8-10 litres for 
a maximum of 10 minutes per nebuliser. Oxygen should then continue through a non-
rebreather mask. 
Oral corticosteroids 
Oral prednisolone should be administered to treat moderate to severe asthma and should be 
given within an hour of presentation. A 3 day course is usually sufficient with dosing 
suggested at 20mg for 2-5 years and 40mg for children aged 5 and above.  As well as tablets, 
prednisolone is now available as a liquid in 1mg/1ml and 10mg/1ml dilution. Providing 
steroids in advance for parents to instigate in the event of a deterioration in asthma control (as 
part of their child’s self-management plan) may be considered, particularly if the family live 
remotely or a previous asthma attack has been severe. Safety net advice should always be 
given, stressing the need for medical review if steroids have been initiated at home. 
Inhalers  
Essentially there are 2 types of devices used to treat asthma:  
• Aerosols e.g. pMDI and breath activated devices e.g. Easibreathe 
• Dry powder inhaler (DPI) e.g. Easyhaler, Accuhaler 
pMDI or breath activated devices contain medication which is already in an aerosol state. A 
slow and steady inhalation is needed. The device needs to be rested for 30 seconds between 
actuations to stabilise back to room temperature. Using a pMDI without a spacer is not 
advisable for any child due to the difficulty with inhalation/ actuation coordination.  A spacer 
with a mask is particularly helpful for pre-school children, though can be used aged 5 years 
and above if the child prefers or has difficulty with a mouthpiece.  
A DPI contains medication in a powder form that needs to be made into an aerosol.  A fast 
and forceful inhalation is needed. Children should be encouraged to carry a personal device 
from around 8 years of age and a DPI tends to be the most cost-effective. There are a number 
of devices available.  Local formulary committees may recommend particular devices.  
It is important for a clinician to become familiar with at least one MDI, breath-actuated MDI 
and DPI as it should be the prescriber’s responsibility to teach and assess inhaler technique 
prior to commencing a new treatment (BTS/SIGN, 2016). Unfortunately, this does not always 
happen and assumptions are made that someone else (for example the community 
pharmacist) will take on this role.  Children and young people’s techniques can be influenced 
by their peers, family members, television and social media and the technique learned this 
way may be incorrect. Inhaler technique should therefore always be assessed at the time of 
issue and at every asthma review.  
Addressing adherence  
Adherence to maintenance asthma treatment is often poor. Addressing non-adherence can be 
made more difficult as causes are often multifactorial and parents often over-estimate 
adherence. It can be helpful to think about non-adherence in two broad categories: intentional 
and non-intentional adherence.  
Intentional non-adherence occurs when children (or their parents) decide not to take the 
recommended treatment after considering the risks and benefits, the impact of their 
symptoms or experience of side-effects (Horne et al., 2006). The term non-intentional non-
adherence applies when children (or their parents) simply forget to use treatment, are unable 
to afford treatment or misunderstand some aspect of the treatment prescribed (Nunes et al., 
2008).  
Asking about adherence in a non-judgemental style, using open questions and acknowledging 
that poor adherence is common. may open up the conversation. Prescribing records can be 
informative: any discrepancy between treatment issued and reported can be a helpful way to 
broach the subject.  
To address intentional non-adherence requires understanding of the child or parents’ ideas 
and concerns – are there doubts about the necessity of the prescribed treatment or concerns 
about potential side-effects? Some children may find taking regular preventer medication 
may not make appreciable difference to symptoms . Discussing these topics openly, 
providing education and making a shared decision are key steps in improving adherence. 
Practical solutions, such as an action plan to consolidate education, a change in inhaler type 
(dry powder rather than MDI) or switching to a once daily combination inhaler, are also 
useful treatment options. 
Summary 
Asthma is common and the basic principles are well-known to medics of all stages. Yet, 
asthma remains a disease that kills, and key evidence-based interventions are still poorly 
implemented. Take pride in providing high quality asthma care, which should include a 
structured approach to diagnosis, prescribing responsibly with clear plans for follow-up, 
checking and discussing adherence to treatment and prioritising regular review as part of 
continuing supported self-management.  
  
 Key points 
• Asthma is the most common long-term condition in childhood and remains a ‘killer 
disease’ 
• Recognition of asthma as a condition that varies in severity and over time is 
important when making a diagnosis 
• A trial of treatment should be for a maximum of 6 weeks following which, treatment 
should be stopped, regardless of the clinical picture, and the child reviewed 
• Address the common discovery of non-adherence to asthma treatment in a non-
judgemental manner  
• Underuse of inhaled corticosteroids (and overuse of short-acting β2 agonists) is 
common and linked to poor asthma control  
• Prioritise asthma self-management in consultations with children over 5 years old  
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Figure 1 Diagnostic algorithm for asthma. 
 
 
Reproduced from BTS/SIGN (2016), British guideline on the management of asthma, with 
permission from SIGN – needs permission.  
  
Figure 2 Summary of management in children.  
 
Key:		
ICS	=	Inhaled	corticosteroid	
LTRA	=	Leukotriene	receptor	antagonist	(e.g.	Montelukast)	
LABA	=	Long	acting	beta	agonist	/	bronchodilator	(e.g.	salmeterol)	
 
 
Reproduced from BTS/SIGN (2016), British guideline on the management of asthma, with 
permission from SIGN – needs permission.  
 
  
Figure 3 Personal asthma action plan for children. 
 
Reproduced from NHS Lothian (2012).  Steps to better asthma care – needs permission 
 
 
  
Figure 4 Assessment and management of acute asthma attack for children.  
 
 
Reproduced from BTS/SIGN (2016), British guideline on the management of asthma, with 
permission from SIGN – needs permission.  
 
Table 1. Symptoms and signs suggesting an alternative diagnosis in wheezy children  
Persistent moist cough 
Cystic fibrosis, bronchiectasis, protracted 
bacterial bronchitis, recurrent aspiration, host 
defence disorder, ciliary dyskinesia 
Excessive vomiting Gastro-oesophageal reflux (± aspiration) 
Paroxysmal coughing bouts leading to 
vomiting Pertussis 
Dysphagia Swallowing problems (± aspiration) 
Breathlessness, with light-headedness and 
peripheral tingling Dysfunctional breathing / Panic attacks 
Inspiratory Stridor Tracheal or laryngeal disorder 
Abnormal voice or cry Laryngeal problem 
Focal signs in chest Development anomaly, post-infective syndrome, bronchiectasis, tuberculosis 
Finger clubbing Cystic fibrosis, bronchiectasis 
Failure to thrive Cystic fibrosis, host defence disorder, gastro-oesophageal reflux disease 
 
Adapted from BTS/SIGN, 2016 
 
 
 
 
 
 
 
 
 
 
Table 2. Assessing the probability of an asthma diagnosis. 
High probability Asthma diagnosis is likely, complete a trial of treatment. 
Low probability An alternative diagnosis is likely, consider further investigation and 
referral as clinically indicated 
Intermediate 
probability 
Diagnosis is uncertain. Additional steps are needed to further evaluate the 
likelihood of asthma: 
• a trial of treatment can be considered, reviewing after a defined period  
• if a child is able, seek confirmation of variable airflow obstruction 
which can be achieved by spirometry or (conveniently in primary 
care) comparing peak expiratory flow when symptomatic with 
readings taken when the child is well. To gain accurate spirometry 
readings in children the operator should have paediatric specific 
training – even then there is a substantial false positive rate.   
• If uncertainty remains despite the further steps taken, refer for a 
specialist opinion. 
Source: BTS/SIGN (2016).  
 
Box 1. Consider referral to secondary care 
• If doubt about diagnosis remains, including failure to respond to a trial of treatment 
• Failure to respond to treatment despite trial of add-on preventer therapies  
• Rapid escalation through therapies 
• Long term high dose (400 microgram daily) inhaled corticosteroids   
• Frequent exacerbations requiring oral steroids 
• Co-existing food allergy, especially to peanuts or tree nuts  
• Parental concern or anxiety 
 
 
